High animal fat intake enhances prostate cancer progression and reduces glutathione peroxidase 3 expression in early stages of TRAMP mice

Chang, Seo Il; Han, Juhee; Abdelkader, Tamer Said; Kim, Tae‐Hyoun; Lee, Ji Min; Song, Juha; Kim, Kyung-Sul; Park, Jong‐Hwan; Park, Jae‐Hak

doi:10.1002/pros.22843

Cited by 44 publications

(46 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, the proven anti-inflammatory properties of specific serenoa, pomegranate and pumpkin extracts [37][38][39]42] which are not directly shared by finasteride, come to be all the more relevant. This has been confirmed last month also in an obese mouse model [43] further paving the way to a wider systemic metabolic understanding of the disease [44][45][46][47]. In favour of such integrated phyto-pharmaceutic approach, it is worthwhile reporting that components such as specific pumking seed, red clover isoflavones, serenoa and pomegranate extracts have been shown to have antiandrogenic activity by dosedependently blocking the binding of DHT besides am anti-aromatase and anti-5-α-reductase Type II action [38,[48][49][50][51].…”

Section: Discussionmentioning

confidence: 68%

Beneficial Effect of a Multifunctional Polyphytocompound in Experimental Prostatic Hyperplasia in Rats

Kantah¹,

Singh²,

Sweed³

et al. 2017

Clin Pharmacol Biopharm

View full text Add to dashboard Cite

The aim of the present study was to assess the efficacy of a poly-phytocompound in a model of experimental BPH. Adult 8 weeks male Wistar rats were subjected to complete orchiectomy under anesthesia (i.p. injection of 100 mg/kg body weight of sodium pentobarbital). After castration, experimental BPH was reproduced by subcutaneous injection of testosterone (20 mg/kg) for 4 weeks and, at the same time, rats randomly divided in 3 groups (15 rats each): (A) untreated BPH model; (B) BPH plus TR10/P3795 orally and (C) BPH plus finasteride (10 mg/kg body weight) administered orally as positive control group. A third group (D) of sham-operated rats served as control. Both TR10/P3795-and finasteride-treated groups showed a significant (p<0.05) and comparable reduction of all morphometric parameters (volume, weight and weight/body weight ration) which were grossly abnormal in untreated BPH model (p<0.01 vs. sham-op.). Moreover, both treatment schedule maintained a near-to-normal 3 h urinary output (p<0.01 vs. untreated BPH). Untreated BPH showed a significant increase of epithelial size and thickness and these features were equally decreased by TR10/P3795 and finasteride (p<0.05). Either TR10/P3795 or finasteride brought about a significant decrease of serum level of DHT and PAP (p<0.05 vs. sham). There was no difference among the two treatments. Prostatic tissue concentration of MDA, IL-6, TNFα and TGFβ1 significantly increased in untreated BPH model (p<0.001). All these parameters significantly decreased, although not normalised, in TR10/P3795-treated group (p<0.05 vs. sham and vs. finasteride). Finasteride determined only a not significant trend decrease of IL-6 and TNFα. Given the multifactorial aetiology of BPH, the data from this experimental model show the promising larger spectrum of mechanisms of action of the tested poly-phytocompound.

show abstract

Section: Discussionmentioning

confidence: 68%

Beneficial Effect of a Multifunctional Polyphytocompound in Experimental Prostatic Hyperplasia in Rats

Kantah¹,

Singh²,

Sweed³

et al. 2017

Clin Pharmacol Biopharm

View full text Add to dashboard Cite

show abstract

“…It is well known that glutathione peroxidases are among the most important reactive oxygen species scavengers that protect cells from oxidative damage (36). Downregulation of GPx3 by hypermethylation has been revealed in numerous types of cancer (37)(38)(39)(40)(41)(42)(43)(44)(45), including prostate cancer (11,46,47). In prostate cancer, a negative correlation between GPx3 expression levels and poor clinical outcomes has been demonstrated (47,48).…”

Section: Discussionmentioning

confidence: 99%

“…In prostate cancer, a negative correlation between GPx3 expression levels and poor clinical outcomes has been demonstrated (47,48). Forced expression of GPx3 in prostate cancer cell lines is able to suppress colony formation and cellular proliferation (11,47,49). Xenografts with higher GPx3 expression levels have resulted in reduced tumor volume, metastasis and animal mortality (47).…”

Section: Discussionmentioning

confidence: 99%

“…They exhibit potential antitumor effects on numerous types of cancers (4)(5)(6)(7)(8)(9)(10), including prostate cancer (11)(12)(13). A previous study performed on prostate cancer cell lines has demonstrated that troglitazone (TGZ) decreases cellular proliferation, which is associated with increased expression levels of glutathione peroxidase 3 (GPx3) (11). TGZ has been investigated in clinical trials against breast, colorectal and prostate cancer (14)(15)(16).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Troglitazone inhibits the migration and invasion of PC‑3 human prostate cancer cells by upregulating E‑cadherin and glutathione peroxidase 3

Chang

Lee

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. Troglitazone (TGZ) is a synthetic peroxisome proliferator-activated receptor γ (PPARγ) ligand that exhibits potential antitumor effects on a number of cancer subtypes, including prostate cancer. However, little is known about the effect of TGZ on metastasis in prostate cancer. The aim of the present study was to determine the inhibitory effect and mechanism underlying TGZ on cell growth, migration and invasion using the prostate cancer PC-3 cell line. Cellular migration and invasion were evaluated by performing a wound healing assay and Matrigel assay, respectively. The expression levels of mRNA and protein were determined by reverse transcription-quantitative polymerase chain reaction and western blotting. The results demonstrated that TGZ dose-dependently inhibited cell migration and invasion of PC-3 cells. The present study also revealed that TGZ increased the mRNA and protein levels of E-cadherin and glutathione peroxidase 3 (GPx3) in human prostate cancer PC-3 cells. In addition, GW9662, a PPARγ antagonist, attenuated the increased mRNA and protein levels of E-cadherin and GPx3, suggesting that the PPARγ-dependent signaling pathway was involved. Taken together, these results suggested that the anti-migration and anti-invasion effect of TGZ on PC-3 prostate cancer cells is, at least in part, mediated via upregulation of E-cadherin and GPx3. The present study also concluded that PPARγ may be used as a potential remedial target for the prevention and treatment of prostate cancer cell invasion and metastasis.

show abstract

“…Down-regulation of GPx3 increases these cell's vulnerability to oxidative damages. Conditions predisposed to prostate cancer, such as high animal fat diet in TRAM mice and loss of tumor suppressor Nkx3.1, has been found accompanied with decrease in GPx3 expression in animal (Chang et al 2014), (Ouyang et al 2005).…”

Section: Prostate Cancermentioning

confidence: 99%

GPX3 (Glutathione peroxidase 3)

Yanping¹,

Luo²

2017

Atlas of Genetics and Cytogenetics in Oncology and Haematology

View full text Add to dashboard Cite

show abstract

High animal fat intake enhances prostate cancer progression and reduces glutathione peroxidase 3 expression in early stages of TRAMP mice

Abstract: Dietary fat enhances prostate cancer progression, possibly by suppressing GPx3 expression and increasing proliferation of prostate intraepithelial neoplasia (PIN) epithelial cells.

Cited by 44 publications

References 36 publications

Beneficial Effect of a Multifunctional Polyphytocompound in Experimental Prostatic Hyperplasia in Rats

Beneficial Effect of a Multifunctional Polyphytocompound in Experimental Prostatic Hyperplasia in Rats

Troglitazone inhibits the migration and invasion of PC‑3 human prostate cancer cells by upregulating E‑cadherin and glutathione peroxidase 3

GPX3 (Glutathione peroxidase 3)

Contact Info

Product

Resources

About